Fennec Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of PEDMARK®, a drug designed to reduce the incidence of hearing loss in children undergoing chemotherapy. The company operates as a single-product entity, having transitioned from a development stage to a commercial stage. PEDMARK® has received marketing approval from the U.S. Food and Drug Administration and the European Commission. The company serves markets in the United States and Europe, with commercialization in Europe and the Gulf Cooperation Council countries managed through third-party partners, including Norgine Pharma UK Limited and Inpharmus. Fennec Pharmaceuticals also conducts clinical studies in Japan, such as the Phase 2 STS-J01 study. The company relies on third-party suppliers for raw materials and contract manufacturers for production, while targeting patient populations with rare diseases associated with chemotherapy-induced ototoxicity.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage fennecpharma.com
Sector Healthcare IR page investors.fennecpharma.com
Tags
oncology, ototoxicity, pediatric, chemotherapy, hearing loss, orphan drug, clinical trials, drug commercialization, PEDMARK®, Norgine Pharma UK Limited, Inpharmus, Fennec Pharmaceuticals Inc.
Press page —

Metrics

Valuation  
Market cap $ 422.58M
Market cap (USD) $ 422.58M
P/E —
PEG —
P/BV 8.59
P/S 6.37
P/OCF 134.19
P/FCF -33.88
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.5%
ROI -27.5%
ROIC -13.3%
Profit margin -21.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 50
Quality score -80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 44.642M 47.538M 23.782M 1.535M — — 0 0 0 0 0 0 0 0 — — — — — —
Net profit -9.741M -436K -16.045M -23.714M -17.346M -18.109M -12.775M -9.888M -7.046M -2.789M -659K -2.176M 1.845M -5.163M 4.685M -7.823M — -20.154M — —
Free cash flow -12.473M 26.98M -17.143M -18.058M -14.222M — — — — — — — -2.21M -2.994M — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 7.7 6.32 11.22 9.6 4.4 7.45 6.48 6.38 10.02 2.24 1.81 2.6 — — — — — — — —
Price performance 12m 0.22 -0.44 0.17 1.18 -0.41 0.15 0.02 -0.36 3.48 0.24 -0.31 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — — — — — 5M — — — —
Lease liabilities (USD) — — — — — — — 23,000 2,000 —
Cash and deposits (USD) 3.93M 28.3M 22.8M 13.7M 30.3M 21.1M 23.8M 13.3M 26.6M 36.8M
Net debt (borrowings + leases - cash) (USD) — — — — — -16.1M — — — —
Cash flow detail
Operating cash flow (USD) -2.12M -3.64M -7.83M -9.06M -15.6M -14.2M -18.1M -17.1M 27M -12.5M
Change in receivables (cash effect) (USD) — — — — — — -1.55M -7.27M -7.87M -12.4M
Change in inventories (cash effect) (USD) — — — — — — -576,000 -1.58M 579,000 -1.28M
Change in payables (cash effect) (USD) -54,000 611,000 177,000 580,000 -41,000 -794,000 1.61M 1.39M -537,000 1.39M
Interest paid (cash effect) (USD) — — — — — — — — -3.82M -4.16M
Income taxes paid (cash effect) (USD) — — — — — — — — — -748,000
Share-based compensation (USD) 615,000 1.52M 1.83M 2.67M 2.79M 3.75M 4.09M 5.35M 5.06M 7.03M
Operating cash flow before change in receivables (USD) — — — — — — -16.5M -9.87M 34.9M -33,000
Income detail
Research and development expense (USD) 472,000 1.94M 5.01M 5.61M 5.11M 4.98M 3.53M 56,000 307,000 250,000
↳ 5y CAGR -20.6% -1.4% +54.0% +73.5% +81.9% +60.2% +12.8% -59.3% -44.1% -45.3%
Provision for credit losses (USD) — — — — — — — — 3.8M 2.1M
Reported Mar 29, 2017 Mar 28, 2018 Mar 15, 2019 Feb 14, 2020 Mar 30, 2021 May 12, 2022 Mar 29, 2023 Mar 29, 2024 Mar 27, 2026 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 06, 2026

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail:

Date: Thursday, November 12, 2026 Time: 8:30 a.m. Eastern Time Webcast Link:https://edge.media-server.com/mmc/p/vuhn59ek Participant Link:https://register-conf.media-server.com/register/BIa5435e66b82346329a08be7e156e3eac

To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

September 17, 2026

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~

~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~

~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interval for Pediatric & Adolescent and Young Adult (AYA) Patients ~

~ Building Upon the Pivotal Children’s Oncology Group (COG) Protocol ACCL0431 & SIOPEL 6 Studies, STS-J01 Represents Third Study to Demonstrate that PEDMARK® Showed No Interference with Cisplatin Antitumor Activity ~

RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan. The data will be presented today during the 58th Annual International Society of Pediatric Oncology (SIOP) Annual Meeting in San Antonio, TX.

PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors, and is also recognized by the National Comprehensive Cancer Network with a 2A endorsement for use in AYA patients.

The study enrolled 33 patients across 11 institutions in Japan, including 27 patients in the primary cohort and six in exploratory cohorts. Key study findings include:

  • Among the 25 patients comprising the primary efficacy population, ASHA-defined hearing loss occurred in 24.0% (6/25), significantly lower than the prespecified historical benchmark of 56.4% (P=0.001).

  • Nineteen of 25 patients (76.0%) remained free of ASHA-defined hearing loss. By Brock criteria, 84.0% of patients had Grade 0 hearing loss, and no patient experienced Grade 3 or Grade 4 hearing loss.

  • Objective tumor responses were observed in 23 of 24 evaluable patients (95.8%), providing reassuring clinical context for delayed PEDMARK® administration six hours following cisplatin.

  • Prospective pharmacokinetic analyses further characterized the interaction between PEDMARK® and cisplatin-derived platinum and provide mechanistic support for the six-hour administration strategy for pediatric and adolescent and young adult (AYA) patients.

“The clinical and pharmacologic findings of STS-J01 are compelling. We observed a significant reduction in hearing loss, with no Grade 3 or Grade 4 hearing loss by Brock criteria, alongside a 95.8% objective response rate in evaluable patients. The prospective pharmacokinetic analyses further provide important mechanistic insight into why the six-hour interval matters, supporting a model in which PEDMARK® acts on residual circulating and exchangeable platinum after cisplatin has had time to distribute and initiate its antitumor activity. Together, these findings add an important independent body of evidence supporting the clinical rationale for delayed PEDMARK® administration,” said Pierre S. Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals.

The safety profile was consistent with the known tolerability profile of PEDMARK® and the expected toxicities of cisplatin-containing chemotherapy. No serious adverse event was attributed to PEDMARK®, and no Grade 4 PEDMARK®-related toxicity was observed.

“For patients navigating cancer in Japan, the ability to successfully treat their tumors while preserving hearing can have a profound impact on their lives long after treatment ends. Cisplatin remains an important and effective treatment, but the risk of permanent hearing loss represents a significant unmet need, particularly for children and young people who may live with its consequences for the rest of their lives,” said Eiso Hiyama, M.D., PhD, lead investigator and professor in the Department of Pediatric Surgery at Hiroshima University Hospital in Hiroshima, Japan. “The results from STS-J01 are encouraging because they demonstrate significant hearing protection and provide reassuring clinical context regarding antitumor activity with delayed PEDMARK® administration. We believe that these results provide further support and confidence in PEDMARK® for healthcare professionals.”

Fennec is pursuing registration in Japan and is currently exploring partnering or licensing opportunities for PEDMARK®.

About the STS-J01 StudySTS-J01 is a Phase 2, investigator-initiated, open-label, single-arm clinical trial designed to evaluate PEDMARK® for the prevention of cisplatin-induced ototoxicity. The study enrolled 33 patients in two cohorts: 27 children ages 3-18 years (primary cohort), and 6 patients in exploratory cohorts, all with localized-stage solid tumors, including neuroblastoma, hepatoblastoma, germ cell tumors, bone and soft tissue sarcomas, medulloblastoma, and atypical teratoid rhabdoid tumors. Patients received PEDMARK® intravenously six hours after cisplatin infusion, with dosing adjusted by body weight. The primary endpoint was the incidence of hearing impairment at the end of treatment in the 3- to 18-year-old cohort, assessed according to American Speech-Language-Hearing Association (ASHA) criteria. Secondary endpoints included safety, antitumor efficacy, pharmacokinetics, and incidence of hearing loss as measured by Brock grading. Exploratory measures included longitudinal audiometric follow-up and validation of surrogate hearing tests.

About Cisplatin-Induced Ototoxicity Cisplatin and other platinum-based chemotherapies are widely used to treat solid tumors and have been vital in improving survival rates. Unfortunately, these life-saving treatments often result in permanent, irreversible hearing loss, also known as ototoxicity.1

Hearing loss from cisplatin treatment is not rare. Studies show that between 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy.2 Many of those treated with cisplatin will require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.3 Treatment-induced hearing loss can reduce quality of survivorship as it impacts many aspects of life, such as speech and language skills, academic performance, social-emotional development, career potential and the ability to live independently.4,5 While audiologic monitoring is recommended to help manage ototoxicity, it is currently underutilized in certain cancer patient populations.

PEDMARK**®****(sodium thiosulfate injection)**PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children’s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Additionally, PEDMARK® is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement.

Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy.6,7 The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of those treated will require lifelong hearing aids. Until the FDA approval of PEDMARK, there were no preventative agents for this hearing loss. Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss.8,9

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L. Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK® at: www.PEDMARK.com.

About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

August 11, 2026

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~

~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~

~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~

~ Real-World Evidence Presented at ASCO 2026 Reinforced that PEDMARK® Can Be Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~

~ Management to Host Conference Call Today at 8:30 a.m. ET ~

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2026 and provided a business update.

“Our second quarter reflects another period of strong execution across the business, highlighted by our seventh consecutive quarter of growth. We continue to build momentum by investing in the evidence that will shape the future of PEDMARK® (sodium thiosulfate), with important data presented at ASCO and a growing pipeline of investigator-sponsored studies that we believe will further expand our understanding of its potential,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “As evidenced in our record EBITDA generation in the second quarter, we have a highly effective business model that is primed to optimize our anticipated growth while advancing our mission to improve outcomes for patients.”

Business Highlights:

  • Continued Commercial Momentum Within Key PEDMARK**®**Accounts: The first full quarter following the expansion of our commercial organization contributed to unprecedented enrollment in the second quarter. Through disciplined execution and now greater reach and frequency to engage with healthcare providers, demand grew across both new and existing accounts, further demonstrating the scalability of our commercial platform. Our commercial, patient services, and medical affairs teams continue to work closely together to help ensure a positive PEDMARK® experience for both prescribers and patients throughout the treatment journey.

  • **2026 American Society of Clinical Oncology (ASCO) Annual Meeting:**New research evaluating PEDMARK® across multiple patient populations and tumor types were shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program. The four independently led studies build upon the established safety and efficacy of PEDMARK® – currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients – and help to expand understanding of the clinical utility of PEDMARK® in Adolescent and Young Adult (AYA) and adult populations, where significant unmet need remains.

Upcoming Events:

  • H.C. Wainwright 27th Annual Global Investment Conference: Fennec will present at the conference to be held September 14 – 17, 2026, in NYC. The management team will also host one-on-one investor meetings at the conference.

Financial Results for the Second Quarter Ended June 30, 2026

  • Net Product Sales– For the second quarter of 2026, the Company recorded net product sales of approximately $17.1 million compared to $9.7 million in the second quarter of 2025. The increase in sales is attributable to growth across PEDMARK® accounts including new accounts in the AYA population.

  • **Selling and Marketing Expenses –**The Company recorded $10.7 million in selling and marketing expenses in the second quarter of 2026 compared to $4.8 million in the second quarter of 2025. The increase is largely related to is largely related to the higher costs associated with the commercialization and increased awareness initiatives of PEDMARK® and related expenses to support the expansion of our sales organization. Further, on a comparable basis, there was a reallocation of select general and administrative expenses to selling and marketing expenses in the second quarter of 2026 compared to the second quarter of 2025.

  • **General and Administrative (G&A) Expenses –**The Company recorded $4.6 million in general and administrative expenses in the second quarter of 2026 compared to $6.5 million in the second quarter of 2025. Thedecrease in general and administrative expenses for the three-month comparable periods due to lower legal and professional fees as select litigation activities concluded. Further, on a comparable basis, there was a reallocation of select general and administrative expenses to selling and marketing expenses in the second quarter of 2026 compared to the second quarter of 2025.

  • Non-GAAP adjusted EBITDA – The Company recorded $2.8 million in non-GAAP adjusted EBITDA in the second quarter of 2026 compared to non-GAAP adjusted EBITDA loss of $1.2 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

  • **Cash Position –**Cash and cash equivalents were $41.2 million as of June 30, 2026 compared to $40.1 million as of March 31, 2026. We anticipate that our cash, cash equivalents and investment securities as of June 30, 2026, combined with the projected revenues from PEDMARK®, will be sufficient to fund our business based on our current operating plan.

Second Quarter 2026 Conference Call Information

Date: Tuesday, August 11, 2026 **Time:**8:30 a.m. Eastern Time Webcast Link:https://edge.media-server.com/mmc/p/2iptdco4 Participant Link:https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3

Financial Update

The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete unaudited condensed consolidated financial statements for the period ended June 30, 2026, and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.

| | | | | | | | | | | | |

| Unaudited Condensed Consolidated Statements of Operations: (U.S. Dollars in thousands except share and per share amounts) |

| | | | | | | | | | | | |

| | | | | | | | | | | | |

| | Three Months Ended | | Six Months Ended |

| | June 30, | | June 30, | | June 30, | | June 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| | | | | | | | | | | | |

| Revenue | | | | | | | | | | | |

| PEDMARK product sales, net | $ | 17,164 | | | $ | 9,652 | | | $ | 32,272 | | | $ | 18,403 | |

| Other revenue | | 710 | | | | — | | | | 710 | | | | — | |

| Total revenue | | 17,874 | | | | 9,652 | | | | 32,982 | | | | 18,403 | |

| | | | | | | | | | | | |

| Operating expenses: | | | | | | | | | | | |

| Cost of product sales | | 721 | | | | 967 | | | | 1,291 | | | | 1,340 | |

| Research and development | | 118 | | | | 107 | | | | 167 | | | | 201 | |

| Selling and marketing | | 10,659 | | | | 4,784 | | | | 22,081 | | | | 8,011 | |

| General and administrative | | 4,639 | | | | 6,526 | | | | 7,825 | | | | 12,391 | |

| | | | | | | | | | | | |

| Total operating expenses | | 16,137 | | | | 12,384 | | | | 31,364 | | | | 21,943 | |

| Income/(loss) from operations | | 1,737 | | | | (2,732 | ) | | | 1,618 | | | | (3,540 | ) |

| | | | | | | | | | | | |

| Other (expense)/income | | | | | | | | | | | |

| Unrealized foreign exchange (loss)/gain | | (6 | ) | | | 17 | | | | (18 | ) | | | 30 | |

| Amortization expense | | — | | | | (13 | ) | | | — | | | | (26 | ) |

| Unrealized loss on securities | | — | | | | (1 | ) | | | — | | | | (2 | ) |

| Interest income | | 287 | | | | 171 | | | | 626 | | | | 407 | |

| Interest expense | | (3 | ) | | | (594 | ) | | | (10 | ) | | | (1,186 | ) |

| Total other expense | | 278 | | | | (420 | ) | | | 598 | | | | (777 | ) |

| Income/(loss) before provision for income taxes | | 2,015 | | | | (3,152 | ) | | | 2,216 | | | | (4,317 | ) |

| Provision for income taxes | | 42 | | | | — | | | | 42 | | | | — | |

| Net income/(loss) | $ | 1,973 | | | $ | (3,152 | ) | | $ | 2,174 | | | $ | (4,317 | ) |

| | | | | | | | | | | | |

| Basic net income/(loss) per common share | $ | 0.06 | | | $ | (0.11 | ) | | $ | 0.06 | | | $ | (0.16 | ) |

| Diluted net income/(loss) per common share | $ | 0.05 | | | $ | (0.11 | ) | | $ | 0.06 | | | $ | (0.16 | ) |

| Weighted-average number of common shares outstanding basic | | 34,545 | | | | 27,664 | | | | 34,596 | | | | 27,621 | |

| Weighted-average number of common shares outstanding diluted | | 36,430 | | | | 27,664 | | | | 37,410 | | | | 27,621 | |

| | | | | | | | | | | | | | | | |

| Fennec Pharmaceuticals Inc. Balance Sheets (U.S. Dollars and shares in thousands) |

| | | | |

| | June 30, | | December 31, |

| | 2026 | | 2025 |

| | | | | | |

| Assets | | | | | |

| | | | | | |

| Current assets | | | | | |

| Cash and cash equivalents | $ | 41,249 | | | $ | 36,788 | |

| Accounts receivable, net | | 23,266 | | | | 23,221 | |

| Prepaid expenses | | 3,635 | | | | 3,738 | |

| Inventory | | 2,374 | | | | 1,565 | |

| Other current assets | | 1,976 | | | | 1,731 | |

| Total current assets | | 72,500 | | | | 67,043 | |

| | | | | | |

| Non-current assets | | 3,253 | | | | 3,508 | |

| Total assets | $ | 75,753 | | | $ | 70,551 | |

| | | | | | |

| Liabilities and stockholders’ deficit | | | | | |

| | | | | | |

| Current liabilities: | | | | | |

| Accounts payable | $ | 5,516 | | | $ | 4,635 | |

| Accrued liabilities | | 3,696 | | | | 5,635 | |

| Contract liability-current | | 3,182 | | | | 248 | |

| Total current liabilities | | 12,394 | | | | 10,518 | |

| | | | | | |

| Long-term liabilities | | | | | |

| Contract liability - long-term | | 20,917 | | | | 24,561 | |

| Total long-term liabilities | | 20,917 | | | | 24,561 | |

| Total liabilities | | 33,311 | | | | 35,079 | |

| | | | | | |

| Stockholders’ deficit: | | | | | |

| Common stock, no par value; unlimited shares authorized; 35,034 shares issued and outstanding (2025 ‑34,163) | | 193,190 | | | | 189,906 | |

| Additional paid-in capital | | 75,257 | | | | 73,745 | |

| Accumulated deficit | | (227,248 | ) | | | (229,422 | ) |

| Accumulated other comprehensive income | | 1,243 | | | | 1,243 | |

| Total stockholders’ deficit | | 42,442 | | | | 35,472 | |

| Total liabilities and stockholders’ deficit | $ | 75,753 | | | $ | 70,551 | |

| | | | | | | | |

| Reconciliation of Net Income/(Loss) to Adjusted EBITDA (Non-GAAP) (U.S. Dollars in thousands) |

| | | | | | | | |

| | Three Months Ended | | Six Months Ended |

| | June 30, | | June 30, | | June 30, | | June 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Net income | $ | 1,973 | | | $ | (3,152 | ) | | $ | 2,174 | | | $ | (4,317 | ) |

| Provision for income taxes | 42 | | | - | | | 42 | | | - | |

| Other revenue (a) | (710 | ) | | - | | | (710 | ) | | - | |

| Interest income | (287 | ) | | (171 | ) | | (626 | ) | | (407 | ) |

| Interest expense | 3 | | | 594 | | | 10 | | | 1,186 | |

| Depreciation and amortization | - | | | 13 | | | - | | | 26 | |

| Share based compensation expense (b) | 1,774 | | | 1,494 | | | 2,764 | | | 2,292 | |

| Unrealized loss on securities | - | | | 1 | | | - | | | 2 | |

| Unrealized foreign exchange gain/(loss) | 6 | | | (17 | ) | | 18 | | | (30 | ) |

| Adjusted EBITDA | $ | 2,801 | | | $ | (1,238 | ) | | $ | 3,672 | | | $ | (1,248 | ) |

| (a) | Represents the portion of GAAP revenue related to “material rights” under the Company’s PEDMARK® license with Norgine that is non-cash in the current period and was previously recorded as deferred licensing revenue. Under ASC 606, a portion of the upfront consideration received under this agreement was allocated to a material right and recorded as deferred revenue (contract liability), which is subsequently recognized as revenue as PEDMARK® units are shipped to Norgine and the related material right is satisfied. These amounts are included in GAAP revenue in the periods presented, and the Company continues to apply GAAP recognition and measurement for all revenue, including this component. The adjustment is intended solely to remove this non-cash amortization of previously deferred licensing revenue from Adjusted EBITDA, as management believes excluding this item provides a more comparable view of period-over-period cash operating performance from the Company’s commercial activities. |

| (b) | Represents share-based compensation expense to account for stock options, restricted stock, and other stock awards over their respective vesting periods. |

| | |

About Cisplatin-Induced Ototoxicity Cisplatin and other platinum-based chemotherapies are widely used to treat solid tumors and have been vital in improving survival rates. Unfortunately, these life-saving treatments often result in permanent, irreversible hearing loss, also known as ototoxicity.1

Hearing loss from cisplatin treatment is not rare. Studies show that between 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy.2 Many of those treated with cisplatin will require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.3 Treatment-induced hearing loss can reduce quality of survivorship as it impacts many aspects of life, such as speech and language skills, academic performance, social-emotional development, career potential and the ability to live independently.4,5 While audiologic monitoring is recommended to help manage ototoxicity, it is currently underutilized in certain cancer patient populations.

PEDMARK**®****(sodium thiosulfate injection)**

PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children’s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Additionally, PEDMARK® is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement.

Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy.6,7 The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of those treated will require lifelong hearing aids. Until the FDA approval of PEDMARK, there were no preventative agents for this hearing loss. Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss.8,9

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L. Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK® at: www.PEDMARK.com.

About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

Prompts

Fennec Pharmaceuticals Inc. (ticker FENC), listed in United States.

Company History

Date Change Detail
Jul 8, 2014 Renamed ADHEREX TECHNOLOGIES INC → FENNEC PHARMACEUTICALS INC.

ETFs Holding Fennec Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
MSSM 0.00% 571 $ 7,051.85 Aug 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
FENC canonical Common share — US nasdaq 12.00 USD 2026-11-13
FRX Common share — CA tsx — —